Orionis Biosciences has announced a multi-year partnership with Roche’s Genentech, focusing on the discovery and development of small-molecule monovalent glue medicines for difficult targets in ...

Orionis Biosciences Announces Collaboration with Genentech to Discover and Develop Molecular Glue Class Medicines Orionis to receive $47 million upfront, as well as future milestone-related payments ...

Roche's Genentech is sticking with Orionis Biosciences, handing over $105 million upfront as part of its second deal with the molecular glue biotech. The latest multiyear collaboration will be ...

Orionis announced its first collaboration with Genentech, to discover novel small-molecule medicines for challenging targets in major disease areas, including oncology and neurodegeneration, in ...

Orionis Biosciences Inc. is sticking with Genentech Inc. in a second deal to discover small-molecule monovalent glue therapies for treating cancer. Privately held Orionis is getting $105 million up ...

Genentech signed onto a $47 million partnership with biotech Orionis Biosciences to focus on discovering novel small molecule therapies across various therapeutic areas, including cancer and ...

Gilead is betting up to $750 million on Kymera’s anti-CDK2 molecular glue for solid tumors, while Sanofi elected to move ...

The multiyear licensing pact with Orionis Biosciences will use the Boston-based biotech’s Allo-Glue platform to discover and optimize molecular glues for targets designated by Genentech.

Orionis Biosciences has announced a multi-year partnership with Roche’s Genentech, focusing on the discovery and development of small-molecule monovalent glue medicines for difficult targets in ...